Ingrid studied Biomedical Sciences at Leiden University. In 2014 she obtained her PhD degree on the use of antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy. Thereafter she worked shortly on regulatory affairs at MSD in Oss. Since 2016 Ingrid held several postdoctoral positions at Newcastle University and Leiden University Medical Center and worked for the DMD patient organisation.
In 2021 Ingrid joined Baggerman Farma Consult as a consultant, focusing on Regulatory Affairs.